Payment overview · 2025
General Payments
$301.69
15 reported records · 9 companies
Healthcare provider profile · identity verified
Edward Suarez, M.D.
Allopathic & Osteopathic Physicians|Physical Medicine & Rehabilitation · MIAMI, FL · NPI 1285697524
Verified facts
What the public records show
CMS Open Payments records show Edward Suarez, M.D. received $301.69 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.14 | 23.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.25 | 16.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.40 | 15.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.09 | 12.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.78 | 8.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.47 | 7.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.81 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.02 | 5.6% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.73 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $301.69 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.14 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.30 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 256 | 43 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 126 | 45 |
| Gabapentin | Gabapentin | 108 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 103 | 39 |
| Clonazepam | Clonazepam | 94 | 17 |
| Metformin Hcl | Metformin Hcl | 94 | 30 |
| Methylprednisolone | Methylprednisolone | 93 | 46 |
| Azithromycin | Azithromycin | 89 | 58 |
| Lisinopril | Lisinopril | 85 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 29 |
| Ibuprofen | Ibuprofen | 75 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 26 |
| Ezetimibe | Ezetimibe | 70 | 27 |
| Omeprazole | Omeprazole | 70 | 25 |
| Losartan Potassium | Losartan Potassium | 66 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 19 |
| Lorazepam | Lorazepam | 58 | suppressed |
| Meloxicam | Meloxicam | 58 | 19 |
| Montelukast Sodium | Montelukast Sodium | 56 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 51 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 28 |
| Baclofen | Baclofen | 48 | suppressed |
| Ozempic | Semaglutide | 48 | suppressed |
| Temazepam | Temazepam | 48 | suppressed |
| Furosemide | Furosemide | 47 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 17 |
| Amoxicillin | Amoxicillin | 43 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 42 | 18 |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | 15 |
| Folic Acid | Folic Acid | 36 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 36 | 16 |
| Nystatin | Nystatin | 35 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 13 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Famotidine | Famotidine | 24 | 11 |
| Glimepiride | Glimepiride | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Clarithromycin | Clarithromycin | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Roxicodone | Oxycodone Hcl | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Alprazolam Er | Alprazolam | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $301.69 · 15 records | Lilly USA, LLC | AIRSUPRA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, LINZESS, MOUNJARO, OTEZLA, REPATHA, The Cologuard Plus Collection Kit, UBRELVY, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error